medical cannabis awareness week 2026 Together for Patients: The Medical Cannabis Leaders Turning Access Into Momentum

Patients first, performance follows

This year’s Medical Cannabis Awareness theme, Together for Patients, comes at a telling moment for investors. The sector’s 2026 leaders are the companies built around patient access.

Cronos Group, Cardiol Therapeutics, Trulieve and Curaleaf are the only medical cannabis stocks we track that are up more than 5% this year. Each reaches patients differently: through international exports, clinical trials, Florida’s medical-only market or cross-border consolidation.

Why it matters now

In April, the U.S. moved state-licensed medical cannabis to Schedule III. The 280E tax relief that follows applies to the full tax year that includes the order’s effective date. Licensed medical operators can now deduct normal business expenses, which directly improves cash flow.

Germany is also driving demand abroad. Rising prescriptions there are fueling exports for Canadian and European producers.

The broader sector has lagged badly, with many large names down 30% or more. That gap makes the leaders’ gains more meaningful.

Four leaders putting patients first

Cronos Group (NASDAQ: CRON) Second-quarter revenue rose 58% to a record $53 million, and gross margin widened to 54%. Its Israeli brand, Peace Naturals, posted a 10th straight record quarter, while revenue from other international markets grew 88%, led by Germany. Cronos holds over $800 million in financial resources. Q3 results on November 5 will test whether that pace can hold.

Cardiol Therapeutics (NASDAQ: CRDL). Cardiol is developing CardiolRx, an oral cannabidiol for heart disease. It hit enrollment for its Phase III MAVERIC trial early, then expanded the trial because patients relapsed less than expected, which delayed results. Three firms rate it a Buy with $9–$11 targets. But Cardiol has no revenue, has issued many new shares, and fell about 31% in the month after the delay.

Trulieve (NYSE: TRLV). The U.S. operator most tied to medical patients runs more than 200 dispensaries in Florida. Q2 revenue reached $271 million at a 60% gross margin. It generated $74 million in first-half free cash flow. In June, it became the first U.S. cannabis operator listed on the NYSE. It is the purest large-cap play on rescheduling, and it reports on November 5.

Curaleaf (OTC: CURLF). Q2 revenue rose 10% to $340.1 million, and international revenue grew 35% in Q1. Its hostile bid for Aurora Cannabis, worth about $5 per share, would create a 17-country operator with more than $1.5 billion in trailing revenue. Aurora’s board has rejected the offer, and Curaleaf shares are down about 19% over the past month.

Investor takeaway

The four leaders share one trait: each built its strategy around patient access, and each has a catalyst ahead. Cronos and Trulieve report November 5. Curaleaf’s Aurora offer runs until December 4. Cardiol’s Phase III trial remains its key driver. 280E relief should also start appearing in U.S. operators’ cash flow.

The risks are real. Volatility remains high. Cardiol depends on a single late-stage trial. Curaleaf faces deal risk before the Alberta Securities Commission, and its U.S. shares still trade over the counter. Full legalization, banking access and interstate trade remain unresolved.

The message of Together for Patients applies to investors too. Companies that earn patients’ trust are earning investors’ as well.